{'fraction_non_alphanumeric': 0.02502844141069397, 'fraction_numerical': 0.013651877133105802, 'mean_word_length': 5.027397260273973, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antilymphocyte antibodies in progressive systemic sclerosis.

Sera from 19 patients with scleroderma were tested for antilymphocyte antibodies (ALA) by indirect immunofluorescence assay. ALA were found in 47% of the cases when tested at 0 degrees, and in 27% at 25 degrees C. Anti-T cell specificity was shown after separation of B and T cells. The heterogeneity of the ALA detected was clear both among different patients and in serum from the same patient. A monoclonal antibody (UCHT1) inhibited ALA binding to T cells completely in one case, and partially in another three, implying that with these 4 sera, the lymphocyte receptors for ALA were either identical or very close to the UCHT1 receptor. This study defines another immunological abnormality in scleroderma: the presence of cold-reactive anti-T cell specific ALA. Their pathogenicity requires further investigation.